Not a good buy right now for an impatient investor: the broader trend remains bearish (SMA_200 > SMA_20 > SMA_5) and there are no Intellectia buy signals.
Today’s +6.21% move looks more like a bounce within a downtrend than the start of a sustained uptrend (MACD still below 0).
Sentiment/positioning is mixed-to-negative: hedge funds are selling aggressively (+323% QoQ selling), while insiders are neutral.
If you already own it, holding makes more sense than chasing this pop; a cleaner buy setup would be after reclaiming key resistance (~1.61 pivot and then ~1.74).
Technical Analysis
Trend: Bearish (SMA_200 > SMA_20 > SMA_5) despite today’s rally; this typically signals rallies can fade.
Momentum: MACD histogram -0.0136 (below 0) but negatively contracting, suggesting downside momentum is easing—not reversed.
RSI(6): 46.66 (neutral), no oversold “snap-back” signal.
Key levels:
Support: S1 1.468, then S2 1.383
Resistance: Pivot 1.606 (near-term line in the sand), then R1 1.743 and R2 1.828
Pattern-based forward bias (historical analogs): ~60% chance of -0.17% next day, +1.33% next week, +7% next month (mildly positive medium-term, but not a strong timing signal).
Gross margin: 100% (suggests revenue mix may be collaboration/other high-margin sources; still, revenue is declining).
Overall: improving losses, but weakening revenue trend keeps fundamentals from supporting an “urgent buy now” decision.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Most recent update (2025-11-12, Chardan): Buy rating maintained; price target cut to $7 from $11 after Q3 results and strategic reprioritization.
What Wall Street pros likely see:
Upside optionality from MGX-001 and platform potential if preclinical progress translates into stronger clinical/milestone outcomes.
CEO change as a potential execution/strategy improvement.
What Wall Street cons likely see:
De-risking of the platform in valuation models (removing platform value) reduces the “multiple expansion” narrative.
Current financial trajectory shows revenue declining and ongoing losses, which can keep pressure on the stock absent a clear catalyst.
Wall Street analysts forecast MGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGX is 8.67 USD with a low forecast of 7 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast MGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGX is 8.67 USD with a low forecast of 7 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.410
Low
7
Averages
8.67
High
12
Current: 1.410
Low
7
Averages
8.67
High
12
Chardan
Geulah Livshits
Buy
downgrade
$11 -> $7
AI Analysis
2025-11-12
Reason
Chardan
Geulah Livshits
Price Target
$11 -> $7
AI Analysis
2025-11-12
downgrade
Buy
Reason
Chardan analyst Geulah Livshits lowered the firm's price target on Metagenomi to $7 from $11 and keeps a Buy rating on the shares after the company reported Q3 results, announced the appointment of Dr. Jian Irish to CEO, and shared updated preclinical data on lead in vivo insertion program MGX-001 in hemophilia A. The firm updated its model for Q3 financials and removed the majority of platform value from the model in light of prioritization.
Chardan
downgrade
$12 -> $11
2025-08-15
Reason
Chardan
Price Target
$12 -> $11
2025-08-15
downgrade
Reason
Chardan lowered the firm's price target on Metagenomi to $11 from $12. The firm updated its model for Q2 financials and takes a slightly more conservative stance on programs/platform beyond hem A and the Ionis collaboration in light of the company's increasing focus on pipeline execution and advancing gene editing platform competition. The firm noted its Q2 adjustments shift its price target lower.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MGX
